NewAmsterdam Pharma Company NV (NASDAQ:NAMS) shares, rose in value on Thursday, November 21, with the stock price up by 0.55% to the previous day’s close as strong demand from buyers drove the stock to $20.12.
Actively observing the price movement in the last trading, the stock closed the session at $20.01, falling within a range of $19.8901 and $21.65. The value of beta (5-year monthly) was -0.001. Referring to stock’s 52-week performance, its high was $26.35, and the low was $8.90. On the whole, NAMS has fluctuated by 4.25% over the past month.
With the market capitalization of NewAmsterdam Pharma Company NV currently standing at about $1.86 billion, investors are eagerly awaiting this quarter’s results, scheduled for in December.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 1.63M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NAMS’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of NAMS currently trading nearly -5.99% and 5.99% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 44.60, while the 7-day volatility ratio is showing 7.34% which for the 30-day chart, stands at 6.51%. Furthermore, NewAmsterdam Pharma Company NV (NAMS)’s beta value is 0.04, and its average true range (ATR) is 1.33.
A comparison of NewAmsterdam Pharma Company NV (NAMS) with its peers suggests the former has fared considerably weaker in the market. NAMS showed an intraday change of 0.55% in last session, and over the past year, it grew by 101.60%%.
Data on historical trading for NewAmsterdam Pharma Company NV (NASDAQ:NAMS) indicates that the trading volumes over the past 10 days have averaged 0.9 and over the past 3 months, they’ve averaged 428.88K. According to company’s latest data on outstanding shares, there are 82.47 million shares outstanding.
Nearly 53.59% of NewAmsterdam Pharma Company NV’s shares belong to company insiders and institutional investors own 40.61% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.72 million shares as on 2024-10-31, resulting in a short ratio of 2.92. According to the data, the short interest in NewAmsterdam Pharma Company NV (NAMS) stood at 129.00 of shares outstanding as of 2024-10-31; the number of short shares registered in 2024-09-30 reached 0.44 million. The stock has risen by 80.13% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NAMS stock heading into the next quarter.
